Bicara Therapeutics (NASDAQ:BCAX) Research Coverage Started at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of Bicara Therapeutics (NASDAQ:BCAXFree Report) in a report released on Tuesday, Marketbeat Ratings reports. The brokerage issued an overweight rating on the stock. Cantor Fitzgerald also issued estimates for Bicara Therapeutics’ FY2024 earnings at ($1.61) EPS.

BCAX has been the subject of several other reports. Stifel Nicolaus initiated coverage on shares of Bicara Therapeutics in a research note on Tuesday. They issued a buy rating and a $47.00 price target for the company. TD Cowen began coverage on Bicara Therapeutics in a report on Tuesday. They issued a buy rating on the stock. Finally, Morgan Stanley started coverage on Bicara Therapeutics in a report on Tuesday. They set an overweight rating and a $35.00 target price for the company.

View Our Latest Research Report on Bicara Therapeutics

Bicara Therapeutics Price Performance

Shares of NASDAQ BCAX opened at $19.00 on Tuesday. Bicara Therapeutics has a one year low of $18.58 and a one year high of $27.94.

Insider Buying and Selling at Bicara Therapeutics

In other news, major shareholder James E. Flynn acquired 70,000 shares of the firm’s stock in a transaction on Tuesday, September 17th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $1,260,000.00. Following the completion of the transaction, the insider now owns 897,587 shares of the company’s stock, valued at $16,156,566. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Bicara Therapeutics news, Director Ra Capital Management, L.P. acquired 1,833,000 shares of the company’s stock in a transaction on Monday, September 16th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $32,994,000.00. Following the acquisition, the director now owns 4,303,418 shares in the company, valued at $77,461,524. This represents a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder James E. Flynn acquired 70,000 shares of the business’s stock in a transaction dated Tuesday, September 17th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $1,260,000.00. Following the completion of the transaction, the insider now owns 897,587 shares in the company, valued at approximately $16,156,566. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here.

Bicara Therapeutics Company Profile

(Get Free Report)

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.

Further Reading

Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.